"With massive amounts of cash being pumped into development by Google, Facebook, Microsoft and context-aware startups such as Flybits, the PA in everybody’s pocket could soon be a reality," Nick…
TORONTO (Dec. 2, 2014) — BlueDot, a Toronto-based social benefit corporation founded by Dr. Kamran Khan, an infectious disease physician and scientist, tracks and predicts the global spread of infectious diseases.
Spun off from St. Michael’s Hospital in partnership with MaRS Innovation (and formerly known as BioDiaspora Inc.), BlueDot, has secured a Series A venture capital funding from Horizons Ventures. Funded by Sir Li Ka-shing, Horizons invests in what they call “game-changing disruptive tech,” and has a proven track record in making early-stage investments (i.e., Facebook, Skype, Waze, Siri and Spotify).
TechVibes and MedCity News covered BlueDot’s Series A announcement, as did PE Hub and BetaKit. Read the BlueDot press release here.
The company is the fourth in MaRS Innovation’s portfolio to reach Series A. MaRS Innovation provided $400,000 in seed funding and worked with BlueDot and St. Michael’s to incorporate the company and develop its initial business strategy, intellectual property protection strategy and go-to-market plan. The Ontario Centres of Excellence also provided $140,000 in commercialization grants that helped BlueDot get off the ground.
BlueDot is the commercial arm of Dr. Khan’s academic research program called BioDiaspora, which was developed at the Li Ka Shing Knowledge Institute of St. Michael’s. BioDiaspora models how infectious diseases can spread and impact populations globally by analyzing big data such as the annual movements of more than 3 billion travelers on commercial flights; human, animal and insect population data; climate data from satellites; and news reports of disease outbreaks. The program was inspired by the Toronto’s SARS crisis in 2003 and its capabilities scientifically validated in prestigious academic journals such as the Lancet and the New England Journal of Medicine.
During its development, BlueDot’s platform technology was used by numerous international agencies, including the U.S. Centers for Disease Control, the World Health Organization, the European Centre for Disease Prevention and Control and the Public Health Agency of Canada to evaluate emerging infectious disease threats, including those during global mass gatherings such as the Olympics and the hajj.
TORONTO, Canada (May 20, 2014) — Red Herring has selected Flybits as one of its 2014 Top 100 North America award winners. Flybits was recognized for its leading-edge, context-aware computing solutions.
Red Herring Top 100 America recognizes innovation from outstanding entrepreneurs and promising companies. Its “Top 100 North America” award winners were selected from among approximately 3,000 tech start-ups financed each year in the U.S. and Canada. Past winners include companies such as Facebook, Twitter, Google, Yahoo, Skype, Salesforce.com, YouTube, Marin Software, Palo Alto Networks and eBay, and many others that have changed how we live and work.
“In 2014, selecting the top 100 achievers was by no means a small feat,” said Alex Vieux, publisher and CEO of Red Herring. “We believe Flybits embodies the vision, drive and innovation that define a successful entrepreneurial venture. Flybits should be proud of its accomplishment, as the competition was very strong.”
On Feb. 13, 2013, almost 100 second-year University of Toronto (U of T) medical students participated in an optional, intensive, one-hour otoscopy workshop using the OtoSim™ — a training and simulation system that is radically changing the way students in Canada and around the world learn this poorly-acquired medical skill.
And, if you want to use simulation technology to change the way medical professionals are taught, ear disease is a good place to start.
Additional photos from this event are posted on OtoSim Inc.’s Flickr account. A longer version of the OtoSim Night at U of T video is also available on the company’s YouTube channel.
“Historically, otoscopy simulation involved looking at an image of an eardrum on a piece of film at the end of a rubber ear,” said Dr. Andrew Sinclair, CEO of OtoSim Inc. “OtoSim™ has a digital image bank that is orders of magnitude more extensive. The instructor can electronically point to areas within the image and confirm that the student sees the pathology of interest. Diagnostic accuracy goes up enormously.”
Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca